Just a quick heads up that the latest addition of the Bio Shares newsletter, dated 01/12, has added CHM to their Class A portfolio and has given a recommendation of a speculative buy rating to their clients.
Interestingly, they define their Class A portfolio as "these stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky that other biotech stocks"
Their summary was "CHM is following a similar and successful portfolio strategy to Imugene, where it is in licensing a suite of discrete immune-oncology drug development assets and is seeking to progress the assets through to rapid proof-of-concept studies".
CHM will not be on offer this cheaply for much longer, especially when it gets noticed by the wider market. Good luck.
CHM Price at posting:
26.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)